Article

Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with.

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with. “Now, until recently that whole idea of risks versus benefits was really about the benefits of the medicine versus the risks of tolerability issues,” said Dr Kantor. “So not of major safety issues.” Self-injectables may be a burden to some, they have a long-term safety profile. Though convenient, newer oral medications have more safety concerns and risks. It is imperative that physicians work with their individual patients to manage risks when using new agents.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr John Mascarenhas
2 experts in this video
2 experts in this video
Dr Pankit Vachhani
Dr John Mascarenhas
Dr John Mascarenhas
Dr Xavier Leleu
Dr Xavier Leleu
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo